Biotech Ventures Forth: Third Rock Rolls Out $426M Fund, Relypsa Reloads
This article was originally published in The Pink Sheet Daily
Executive Summary
It was a good day for biotech venture news, as early-stage investor Third Rock closed its second fund and Relypsa reported a massive $70 million Series B funding to push its potassium binding agent into pivotal trials.
You may also be interested in...
Third Rock Continues To Attract Investors, Closes $516M Fund
The biotech venture firm continues to draw investors despite lacking a large number of exits for its portfolio companies. Its third fund brought in the largest investment yet for the firm.
Third Rock Ventures Pumps $38 Million Into New Firm Focused On Genetic Heart Disease
Third Rock is the sole Series A investor in MyoKardia, which plans to use personalized medicine to treat hypertrophic and dilated cardiomyopathies.
Relypsa Adds Venture Funds In Another Effort To Reach Phase III
Relypsa, spun out from Amgen in 2007, has raised a third round of financing in an effort to move its lead compound into late-stage development.